Dr. Martens plc (FRA:3U2)
Germany · Delayed Price · Currency is EUR | Market Cap | 751.24M -28.1% |
| Revenue (ttm) | 882.34M -2.9% |
| Net Income | 27.45M +428.9% |
| EPS | 0.03 +413.3% |
| Shares Out | n/a |
| PE Ratio | 27.36 |
| Forward PE | 13.13 |
| Dividend | 0.03 (3.97%) |
| Ex-Dividend Date | Aug 27, 2026 |
| Volume | n/a |
| Open | 0.7450 |
| Previous Close | 0.7450 |
| Day's Range | 0.7450 - 0.7450 |
| 52-Week Range | 0.6600 - 1.1100 |
| Beta | n/a |
| Analysts | n/a |
| Price Target | n/a |
| Earnings Date | Nov 27, 2026 |
About Dr. Martens
Dr. Martens plc engages in the design, development, procurement, marketing, sale, and distribution of footwear. The company sells its footwear under the Dr. Martens brand name in Europe, the Middle East, Africa, the Americas, and the Asia-Pacific. Dr. Martens plc was founded in 1945 and is based in London, the United Kingdom. [Read more]
Financial Performance
In fiscal year 2026, Dr. Martens's revenue was 764.90 million, a decrease of -2.88% compared to the previous year's 787.60 million. Earnings were 23.80 million, an increase of 428.89%.
Financial numbers in GBP Financial StatementsNews
Dr. Martens Earnings release: Trading update
Dr. Martens released its earnings on July 15, 2026, summarizing the period's financial results.
Dr. Martens H2 Earnings Call Highlights
Dr. Martens LON: DOCS reported higher full-year profit despite slightly lower revenue, as management said the footwear brand prioritized full-price sales, reduced markdown activity and continued to re...
Dr. Martens Earnings Call Transcript: H2 2026
Revenue declined 1.4% but profit before tax rose 61% as the business prioritized full-price sales and reduced markdowns, especially in the US and APAC. Net debt fell, margins improved, and new retail concepts and markets were launched, with a focus on further growth in FY 2027.
Dr. Martens Annual report: H2 2026
Dr. Martens has published its H2 2026 annual report on May 19, 2026.
Dr. Martens Slides: H2 2026
Dr. Martens has posted slides in relation to its H2 2026 quarterly earnings report, which was published on May 19, 2026.
Dr. Martens Annual report: H2 2026
Dr. Martens has published its H2 2026 annual report on May 19, 2026.
Dr Martens' turnaround gathers pace as annual profit jumps 61%
Dr Martens reported a 61% jump in annual earnings on Tuesday and forecast "strong profit" growth this fiscal year as the British bootmaker's strategy of cutting discounts and improving margins appear...
Dr. Martens Earnings Call Transcript: Q3 2026
Q3 saw accelerated growth in the Americas, strong wholesale gains across all regions, and robust performance in shoes, while EMEA retail lagged due to a tough consumer environment. Inventory and cost controls remain strong, and early U.S. price increases show no negative impact.
Dr. Martens Earnings release: Q3 2026
Dr. Martens released its Q3 2026 earnings on January 27, 2026, summarizing the period's financial results.
Dr. Martens Revenue Drops on Europe, Middle East and Africa Weakness
Chief Executive Ije Nwokorie said the EMEA market continued to be challenging, and that the company had taken a more disciplined promotional stance there.
Dr. Martens Earnings Call Transcript: H1 2026
Revenue and profit improved year-on-year, driven by higher full-price sales, cost control, and growth in the Americas and APAC. Strategic execution is on track, with new product launches, expanded partnerships, and technology investments supporting future growth.
Dr. Martens Quarterly report: H1 2026
Dr. Martens has published its H1 2026 quarterly earnings report on November 20, 2025.
Dr. Martens Slides: H1 2026
Dr. Martens has posted slides in relation to its H1 2026 quarterly earnings report, which was published on November 20, 2025.
Dr. Martens Earnings release: Trading Update
Dr. Martens released its earnings on July 10, 2025, summarizing the period's financial results.
Dr. Martens Transcript: Strategy Update
A new consumer-first strategy aims to drive sustainable, profitable growth by broadening product offerings, optimizing market-specific distribution, and leveraging brand strengths. Financial discipline, operational improvements, and technology investments support mid to high teens EBIT margin targets over the medium term.
Dr. Martens Slides: Strategy Update
Dr. Martens has posted slides in relation to its latest quarterly earnings report, which was published on June 5, 2025.
Dr Martens forecasts return to profit growth, shares jump
British bootmaker Dr Martens forecast a return to profit growth in the current financial year on Thursday, backed by its new CEO's plan to put more emphasis on shoes, sandals, and bags, as well as the...
Dr. Martens Earnings Call Transcript: H2 2025
Stabilization achieved in FY25 with Americas DTC growth, cost reductions, and significant inventory and debt improvements. Revenue and EBIT declined YoY but met guidance, while strong cash flow and disciplined cost management set up for future growth.
Dr. Martens Annual report: H2 2025
Dr. Martens has published its H2 2025 annual report on June 5, 2025.
Dr. Martens Annual report: H2 2025
Dr. Martens has published its H2 2025 annual report on June 5, 2025.
Dr. Martens Slides: H2 2025
Dr. Martens has posted slides in relation to its H2 2025 quarterly earnings report, which was published on June 5, 2025.
Dr. Martens Selects Amperity to Transform Customer Data Strategy
LONDON--(BUSINESS WIRE)-- #AdTech--Amperity, an AI-powered customer data cloud, today announced Dr. Martens, an iconic British brand, has selected its platform to support its global data and marketing...
Dr. Martens Earnings Call Transcript: Q3 2025
Q3 results met expectations with USA DTC up 4% and APAC strong, while EMEA was flat due to less discounting. Guidance is unchanged, inventory is down, and cost savings are on track. Product-led marketing and new products are driving positive momentum.
Dr. Martens Earnings release: Q3 2025
Dr. Martens released its Q3 2025 earnings on January 27, 2025, summarizing the period's financial results.
Dr. Martens Shares Soar Despite H1 Loss
Shares of the UK-based Dr. Martens PLC ($GB:DOCS) soared 13% as of writing, despite the company reporting a loss in its H1 results for FY25. The footwear company, known for…